$17.50
1.30% day before yesterday
Nasdaq, Dec 27, 10:04 pm CET
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

uniQure N.V. Stock price

$17.50
+11.48 190.70% 1M
+12.96 285.46% 6M
+10.73 158.49% YTD
+10.70 157.35% 1Y
-3.98 18.53% 3Y
-55.00 75.86% 5Y
+1.87 11.96% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.23 1.30%
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

Key metrics

Market capitalization $853.00m
Enterprise Value $912.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 31.90
P/S ratio (TTM) P/S ratio 29.84
P/B ratio (TTM) P/B ratio 15.28
Revenue growth (TTM) Revenue growth -74.45%
Revenue (TTM) Revenue $28.59m
EBIT (operating result TTM) EBIT $-203.11m
Free Cash Flow (TTM) Free Cash Flow $-184.69m
Cash position $435.24m
EPS (TTM) EPS $-4.96
P/E forward negative
P/S forward 20.79
EV/Sales forward 22.23
Short interest 6.74%
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a uniQure N.V. forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a uniQure N.V. forecast:

Buy
83%
Hold
17%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
29 29
74% 74%
100%
- Direct Costs 39 39
137% 137%
136%
-10 -10
111% 111%
-36%
- Selling and Administrative Expenses 34 34
36% 36%
120%
- Research and Development Expense 146 146
11% 11%
510%
-191 -191
55% 55%
-667%
- Depreciation and Amortization 12 12
24% 24%
44%
EBIT (Operating Income) EBIT -203 -203
53% 53%
-710%
Net Profit -240 -240
5% 5%
-838%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Positive
The Motley Fool
14 days ago
Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.
Positive
Investors Business Daily
19 days ago
UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment. The post UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
19 days ago
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 480
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today